2017 Fiscal Year Final Research Report
Pathophysiology and developing mechanism, and structure and toxicity of insulin-derived amyloidosis
| Project/Area Number |
15K08597
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岩屋 啓一 公益財団法人佐々木研究所, 附属研究所, 研究員(移行) (50312012)
座古 保 愛媛大学, 理工学研究科(理学系), 教授 (50399440)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KATSURA YOSHIYA 東京医科大学, 医学部, 教授 (90266487)
|
|---|
| Project Period (FY) |
2015-10-21 – 2018-03-31
|
| Keywords | インスリン / アミロイドーシス / 病態 / MRI / 予後 / 構造 / 毒性 |
|---|
| Outline of Final Research Achievements |
Insulin-derived amyloidosis is a skin-related complication of insulin therapy. The amyloid fibril protein is derived from the injected insulin and forms an amyloid deposit at the injection site. The present study showed the clinical charascteristics and long-term prognosis of insulin-derived amyloidosis. Additionally, the study investigated the prevalence of insulin-derived amyloidosis by screening insulin injection sites using MRI in patients with insulin-treated diabetes. Moreover, this study indicated the structure and toxicity of insulin-derived amyloidosis. Thus, the present study showed the pathophysiology of insulin-derived amyloidosis more clearly, and cotributed to the improvement in insulin therapy.
|
| Free Research Field |
代謝内分泌学
|
